Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could a common diabetes drug stop diabetes after kidney transplant?

NCT ID NCT07682350

Prevention Sponsor: Odense University Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 02, 2026 · Last updated Jul 02, 2026

Summary

This trial tests whether taking dapagliflozin (Forxiga) for 12 months can prevent post-transplant diabetes in kidney transplant recipients who do not have diabetes. The study includes 184 adults who recently received a kidney transplant and are on standard immunosuppressive therapy. Participants are randomly assigned to receive either dapagliflozin or a placebo, and researchers monitor diabetes development, kidney function, and safety over a year.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Dapagliflozin (Forxiga)
What this could lead to
If it works, this could offer a way to prevent diabetes after kidney transplant, helping patients avoid a lifelong condition and protecting their new kidney.
What could go wrong
This is a Phase 2 trial with 184 participants, so results are preliminary. The drug may not reduce diabetes risk or could cause side effects like urinary infections or kidney issues.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

About 184 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Sep 2026

An estimate. Start dates often move.

Expected to finish

Oct 2029

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Obtained written informed consent * Male or female patients, age ≥ 18 years. * Non-diabetic KTR * Immunosuppressive must include Tacrolimus Exclusion Criteria: * Patients who is treated (diet or antidiabetics) for diabetes type 1 or 2 before randomization * eGFR\< 25 ml/min/1.73m2 (before randomization) * Alanine aminotransferase (ALAT) \> 3 x upper normal limit * Bilirubin \> 2 x upper normal limit * Pregnancy * Positive plasma hCG * Breastfeeding * Known allergy towards SGLT2i or the content substance * Patients with chronic intestinal diseases, including inflammatory bowel diseases (e.g., Crohn's disease and ulcerative colitis) and structural conditions such as short bowel syndrome.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Kidney transplant recipient are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Kidney transplant recipient Non-diabetic patients Placebo control design Post transplant diabetes mellitus Randomized controlled trial (RCT) Sodium glucose co-transporter 2 inhibitors

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    3 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Department of Nephrology and Endocrinology.

    Copenhagen, 2100, Denmark

  • Department of Nephrology, Odense University Hospital

    Odense, 5000, Denmark

  • Department of Renal Medicine

    Aarhus, 8200, Denmark

More trials for these conditions

Other studies related to the condition(s) this trial covers.